NZ504445A - Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive - Google Patents

Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive

Info

Publication number
NZ504445A
NZ504445A NZ504445A NZ50444596A NZ504445A NZ 504445 A NZ504445 A NZ 504445A NZ 504445 A NZ504445 A NZ 504445A NZ 50444596 A NZ50444596 A NZ 50444596A NZ 504445 A NZ504445 A NZ 504445A
Authority
NZ
New Zealand
Prior art keywords
high mobility
contraceptive
genes
nucleic acid
acid sequences
Prior art date
Application number
NZ504445A
Other languages
English (en)
Inventor
Jorn Bullerdiek
Original Assignee
Jorn Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jorn Bullerdiek filed Critical Jorn Bullerdiek
Publication of NZ504445A publication Critical patent/NZ504445A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ504445A 1995-12-21 1996-12-20 Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive NZ504445A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19548122A DE19548122A1 (de) 1995-12-21 1995-12-21 Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben

Publications (1)

Publication Number Publication Date
NZ504445A true NZ504445A (en) 2002-08-28

Family

ID=7781000

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504445A NZ504445A (en) 1995-12-21 1996-12-20 Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive

Country Status (7)

Country Link
EP (1) EP0870024A2 (xx)
JP (3) JP2000504933A (xx)
AU (1) AU1870597A (xx)
CA (1) CA2239682A1 (xx)
DE (1) DE19548122A1 (xx)
NZ (1) NZ504445A (xx)
WO (1) WO1997023611A2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824230A1 (de) * 1998-05-29 1999-12-02 Starzinski Powitz Anna Neues Endometriose-assoziiertes Gen
DE19904514A1 (de) * 1999-02-04 2000-08-10 Joern Bullerdiek Mittel zur Prävention und/oder Behandlung von Leiomyomen
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
WO2001029080A1 (fr) * 1999-10-18 2001-04-26 Shanghai Bio Road Gene Development Ltd. Nouveau polypeptide, une proteine humaine hmg-13, et polynucleotide codant pour ce polypeptide
CN1300762A (zh) * 1999-12-23 2001-06-27 复旦大学 一种新的多肽－高迁移率组分蛋白家族11和编码这种多肽的多核苷酸
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
JP2005511770A (ja) * 2001-12-19 2005-04-28 アルケド バイオテック ゲーエムベーハー Ｈｍｇｂタンパク質およびｈｍｇｂタンパク質をコードする核酸の使用方法
ATE424416T1 (de) * 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
AU2004203732A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of HMGB, HMGN, HMGA proteins
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005026209A2 (en) 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
EP1812065A4 (en) 2004-10-22 2009-09-02 Medimmune Inc HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279941A (en) * 1992-06-12 1994-01-18 Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
EP0727487A1 (en) * 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes

Also Published As

Publication number Publication date
JP2010029207A (ja) 2010-02-12
JP2000504933A (ja) 2000-04-25
AU1870597A (en) 1997-07-17
WO1997023611A2 (de) 1997-07-03
DE19548122A1 (de) 1997-06-26
CA2239682A1 (en) 1997-07-03
EP0870024A2 (de) 1998-10-14
WO1997023611A3 (de) 1997-10-02
JP2007312778A (ja) 2007-12-06

Similar Documents

Publication Publication Date Title
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
Beal et al. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
AU3368497A (en) Human dnase i hyperactive variants
WO1991004316A3 (en) Ciliary neurotrophic factor
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
NO973685L (no) Multi-tumor avvikende vekstgener
CA2284859A1 (en) Nucleic acid molecule for a human skeletal muscle-specific receptor
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
DE69834727D1 (de) 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
ES2139578T3 (es) Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.
HK1002531A1 (en) New tumor diagnosing or therapeutical probe
EP1169441B8 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
EP0652948A4 (en) CREATION OF A VECTOR CALLED TO TARGETE GENE EXPRESSION IN THE EPIDERMIS OF TRANSGENIC ANIMALS.
HUP0201868A2 (en) Antisense therapy for hormone-regulated tumors
WO2000008157A3 (en) Human anion transporter genes atnov
AU2001233957A1 (en) Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
EP0527941A4 (xx)
DE69730967D1 (en) Human dnase ii

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired